Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence

被引:9
|
作者
Rajesh, V [1 ]
Augustine, Jolsana [1 ]
Divya, R. [1 ]
Cleetus, Melcy [1 ]
机构
[1] Rajagiri Hosp, Dept Pulm Med, Kochi, Kerala, India
关键词
FIXED-DOSE COMBINATION; ADULT PATIENTS; DRY-POWDER; RELATIVE BIOAVAILABILITY; OPEN-LABEL; PROPIONATE; ONSET; BUDESONIDE/FORMOTEROL; SALBUTAMOL; ADOLESCENT;
D O I
10.1155/2020/8631316
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment
    Joplin, Hannah
    Mclenaghan, Daniella
    Jones, Lewis
    Robinson, Ryan
    Hunter, Karl
    Lowe, Catherine
    Flynn, Victoria
    Root, Laura
    Burhan, Hassan
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [42] Real-world impact of non-clinical inhaler switching on asthma or COPD patients: A systematic review
    Bell, John
    Usmani, Omar
    Bosnic-Anticevich, Sinthia
    Dekhuijzen, Richard
    Lavorini, Federico
    Stjepanovic, Neda
    Swift, Stephanie L.
    Roche, Nicolas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 344 - 345
  • [43] Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
    Salvi, Sundeep
    Balki, Akash
    Krishnamurthy, Srikanth
    Panchal, Sagar
    Patil, Saiprasad
    Kodgule, Rahul
    Khandagale, Hitesh
    Pendse, Amol
    Wu, Wen
    Rangwala, Shabbir
    Tandon, Monika
    Barkate, Hanmant
    ERJ OPEN RESEARCH, 2021, 7 (03)
  • [44] Development of a registry to assess adherence and digital inhaler utilization in real-world patients with asthma (AURORA): a modified Delphi study
    Wiertz, Mechteld
    Eikholt, Amber
    Ten Brinke, Anneke
    Weersink, Els
    Kerstjens, Huib
    Van Weerdt, Irene
    In 'T Veen, Johannes
    Patberg, Kornelis
    Goosens, Martijn
    Chavannes, Niels
    Been-Buck, Sandra
    Klemmeier, Titia
    Van Boven, Job
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [45] The Use of Inflammation Parameters in the Care of Patients with Asthma Prescribed Extrafine Single-Inhaler Triple Therapy: A Real-World View from Germany
    Gessner, C.
    Akyildiz, B.
    Nachtigall, D.
    Nudo, E.
    Boeing, S.
    Timmermann, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [46] Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management
    Park, Hee Sun
    Lee, Jungkuk
    Kim, Hasung
    Woo, Seong-Dae
    RESPIRATORY RESEARCH, 2025, 26 (01)
  • [47] Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan
    Suzuki, Takeo
    Fairburn-Beech, Jolyon
    Sato, Keiko
    Kaise, Toshihiko
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 1049 - 1057
  • [48] Improvement of treatment adherence after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
    Gessner, C.
    Akyildiz, B.
    Grickschat, V
    Borucki, T.
    Trinkmann, F.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [49] Increasing Asthma Therapy As Extrafine Hydrofluoroalkane Beclomethasone Or Fluticasone: A Real-World Comparative Effectiveness Study From The United States
    Martin, R.
    Colice, G.
    Barnes, N.
    Roche, N.
    Lee, A. J.
    Dorinsky, P.
    Polos, P.
    Chisholm, A.
    von Ziegenweidt, J.
    Burden, A.
    Hillyer, E. V.
    Price, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [50] Change in asthma control after 6 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
    Greulich, T.
    Akyildiz, B.
    Nachtigall, D.
    Bogoevska, V
    Gessner, C.
    PNEUMOLOGIE, 2023, 77 : S29 - S29